9/2/2023 0 Comments Keynote 407![]() Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “The overall survival findings from KEYNOTE-189 and KEYNOTE-407 changed the way patients with metastatic non-small cell lung cancer were treated and established KEYTRUDA plus chemotherapy as a foundational first-line treatment for this devastating disease,” said Dr. In addition to NSCLC, five-year survival data for KEYTRUDA have been presented in three other types of cancer, including bladder cancer (KEYNOTE-045), head and neck cancer (KEYNOTE-048) and melanoma (KEYNOTE-054). KEYTRUDA is the first immunotherapy to demonstrate a sustained five-year survival benefit both in combination with chemotherapy and as monotherapy for the first-line treatment of NSCLC. The median OS was 17.2 months for the KEYTRUDA plus chemotherapy group versus 11.6 months for the chemotherapy group. KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel reduced the risk of death by 29% (HR=0.71 ) versus chemotherapy alone. At five years, KEYTRUDA plus pemetrexed and cisplatin or carboplatin more than doubled the median OS compared to chemotherapy alone (22.0 months versus 10.6 months) įor patients with metastatic squamous NSCLC, results from KEYNOTE-407 showed the five-year OS rate for KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel was 18.4% versus 9.7% for chemotherapy alone. ![]() The KEYTRUDA-pemetrexed-platinum chemotherapy combination reduced the risk of death by 40% (HR=0.60 ). Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy continued to demonstrate a survival benefit and durable responses in two five-year exploratory analyses of pivotal Phase 3 studies as first-line treatment for metastatic non-small cell lung cancer (NSCLC):įor patients with metastatic nonsquamous NSCLC, data from KEYNOTE-189 demonstrated KEYTRUDA plus pemetrexed (ALIMTA ®) and platinum chemotherapy (cisplatin or carboplatin) had a five-year overall survival (OS) rate of 19.4% versus 11.3% for chemotherapy alone. In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |